FDA Expands Enhertu Approval to HER2-Ultralow Breast Cancer

By News Health
1 month Ago

(MedPage Today) — The FDA expanded the approval of trastuzumab deruxtecan (T-DXd, Enhertu) to include treatment of unresectable/metastatic hormone receptor (HR)-positive, HER2-low/ultralow breast cancer.
Approval stipulates use in patients with…

Source link : https://www.medpagetoday.com/hematologyoncology/breastcancer/113982

Author :

Publish date : 2025-01-28 20:41:44

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Autotaxin Levels Are Elevated in Patients With Migraine

Poor Adherence to Post-Cervical Dysplasia Care Guidelines

Understanding the Geographic Distribution of PAs in the US

Compounders Face Deadline to Stop Manufacturing Tirzepatide

AI-Based Skin Cancer Screen Effective in Real

New Bat Coronavirus Being Watched